7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 1/38


Short Ideas  |  Healthcare   |  Editors' Picks


Abeona: Stock Promotions, Fraud Convictions, And Demonstrably
Unviable Science ­ A Sell With 92% Downside
Dec. 12, 2016 9:30 AM ET77 comments
by: Mako Research


Summary


ABEO science is demonstrably unviable with numerous irrefutable flaws that will
lead to failure, with yet another single location NCH “trial” design.


Former ABEO insider and largest shareholder David Blech convicted of securities
fraud. Since then, this “company” has seen more asset shuffling than a card table in
Vegas.


Stock promoters responsible for numerous biotech wipeouts run this “company,”
while ABEO temporarily trades near the highest market capitalization in its 20­year
history, while going concern questions abound.


ABEO’s auditor Whitley Penn cited by PCAOB repeatedly for “audit deficiencies”.
This is the same tiny auditor who oversaw the alleged UDF “Ponzi scheme” exposed
by Kyle Bass.


Insiders have collected a shocking ~$35m in compensation, which exceeds 50% of
ABEO’s R&D spending since 1996, while losing over $325m of shareholder cash,
and yet accomplishing apparently nothing.


I believe Abeona Therapeutics (NASDAQ:ABEO) is a reverse merger trading at a bubble
valuation of ~$200 million market capitalization despite demonstrably unviable science
and ties to some of the worst biotech executives of the last 20+ years. These insiders
have accumulated multi­decade track records of shareholder wreckage including several
prior companies that went to essentially zero. Due to stock promotion ties and retail
shareholder confusion about scientific sounding press releases, ABEO currently trades
near the highest market capitalization in its history. As a result, ABEO is set to decline
92% as its science fails and the stock promotion comes unwound, just like other Steven
Rouhandeh biotech stocks.


Meanwhile, the company is pursuing their "science" at the most questionable single­center
location in America: the disgraced Nationwide Children's Hospital (NCH) of Sarepta
(NASDAQ:SRPT) (and now AveXis (NASDAQ:AVXS)) infamy. We show that ABEO's trial



https://seekingalpha.com/stock-ideas/short-ideas

https://seekingalpha.com/stock-ideas/healthcare

https://seekingalpha.com/stock-ideas/editors-picks

https://seekingalpha.com/symbol/ABEO

https://www.bamsec.com/transcripts/5869152?hl_id=ejzuyvb7g

https://seekingalpha.com/symbol/SRPT

https://seekingalpha.com/symbol/AVXS
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 2/38


design has multiple serious flaws which render ABEO's science completely unviable.
Simultaneously, superior competitors are emerging that offer superior treatments, all vying
for a miniscule total addressable market in a rare disease that leaves ABEO's valuation
unsustainable even if its gene therapy treatments ever miraculously work (which will never
happen).


Perhaps explaining ABEO's true reason for existence, ABEO appears to be a bottomless
pit of self­enrichment for the long­time stock promoters who run this "company" with
apparently minimal oversight: the auditor in charge of reviewing ABEO's financials is the
very same auditor responsible for overseeing alleged "Ponzi scheme" United
Development Funding (UDF) that was exposed by famed hedge fund investor Kyle Bass.
A deeper look revealed that virtually all of this auditor's publicly traded clients suffered
substantial price losses over time. Given the complex web of insider related party
transactions at ABEO, the extremely questionable team here with a long history of biotech
wipeouts, and the $325m of shareholder losses vs. just $35m of R&D spend (where did all
the money go?), how can anyone trust the financial statements of this company?


Once the stock promotion ends and as ABEO's clinical trials prove unviable, we expect
the stock to mean revert to a level much lower than today, and at a minimum in line with
the ~$30m market cap it has been at for virtually its entire life and as recently as 2014.


My research and opinions are presented here free of charge for the benefit of the public
good. I encourage everyone to conduct their own due diligence and research to form their
own conclusions.


Our Research Shows Abeona's "Science" Is Unviable, Rife with Conflicts, and Set
to Fail


In this report we share research that we believe definitively and irrefutably demonstrates
ABEO's science is completely unviable, calling into question the very reason for the
company's existence.


For background, Abeona claims to be pursuing gene therapy applications to treat
Sanfilippo syndrome by primarily focusing on clinical development of two drugs: ABO­102
(Sanfilippo Type A MPS IIIA) and ABO­101 (Type B MPS IIIB). Readers unfamiliar with
Sanfilippo syndrome may want to read a basic primer before continuing through this
report. Essentially, Sanfilippo syndrome is an inherited monogenic disorder that causes
lysosomal enzyme deficiency, which manifests in delayed speech onset, behavioral
problems, sleep disturbance, and progressive intellectual decline. The onset of the
condition begins at birth and typically results in death in the late teens or early 20's. As



https://en.wikipedia.org/wiki/Sanfilippo_syndrome
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 3/38


with other gene therapy approaches, Abeona's treatments attempt to use a virus injected
into a patient to transport the correct gene sequence into cells, which, if successful, would
alter the patient's DNA in order to correct the genetic disorder. Readers can learn more
about the basics of Abeona's approach by referring to the company's own corporate
presentation. Additional perspective about gene therapy treatments is available in my prior
report on gene therapy peer Avexis. For the purpose of brevity, this report assumes the
reader already has basic familiarity with the scientific nomenclature and background
regarding these topics.


This report will cover the following key points about Abeona's science:


Three serious flaws in Abeona's gene therapy approach guarantee failure of ABO­101 and
ABO­102. Furthermore, ABEO does not appear to be pursuing a rational regulatory
pathway forward, calling into question the true motives of insiders as they continue to
collect their ridiculously excessive insider compensation paid for with shareholder money.
Similar to AVXS, ABEO has pursued flakey trials at a single location ­ the Nationwide
Children's Hospital (NCH) in Ohio. As I wrote about previously in my report on AVXS, NCH
faces a host of related party conflicts of interest, negative media coverage after the
Sarepta fiasco, and a tainted reputation that casts significant doubt over the limited data
studies conducted at NCH. Lastly, even if Abeona ever made its way through all of the red
flags above, the TAM of Sanfilippo syndrome is incredibly small, and ABEO faces a host of
larger competitors pursuing superior treatments in this small and crowded market.


With ABEO, investors appear under the mistaken belief that adeno associated virus (AAV)
based gene therapy approaches are a cure all for monogenic diseases like Sanfilippo
syndrome. They don't dig into the scientific details and as such are susceptible to
believing the superficial analysis conducted by conflicted sell side banks and stock
promoters. This certainly seems to be the case with Abeona as a deep dive into the
medical literature reveals not one but three key flaws in Abeona's approach, any of
which would render their claims unviable.


First, a primer on gene therapy. In order for gene therapy to work, the gene in question
has to get to the target cell AND it has to express once it is there. The first part, called
delivery, is typically accomplished by a virus. The second is accomplished through the use
of a promoter. In other words, there are two key steps that must both be successful for the
gene therapy treatment to work. The promoter (pun intended in the case of Abeona)
directs expression of the gene of interest once the virus has transduced the tissue.
Promoters come in two types: constitutive (always on) and tissue specific (only work in
certain tissues). With that as a background, let us explore why Abeona's approach fails



https://seekingalpha.com/article/4024171-avexiss-house-cards-dubious-trials-drug-lawsuit-fraud-allegations-strong-sell-94-percent?v=1480787743&commenter=1&comments=show
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 4/38


these two criteria, which in turn makes ABO­101 and 102 destined to certain failure based
on our research. Furthermore, we then show that ABEO has no rational regulatory
pathway forward.


Abeona Flaw #1: AAV gene therapy has already been tried in MPS3a and hasn't
worked


We rarely have a case where we can compare direct delivery with indirect delivery for the
same disease but it turns out Abeona is not the first to consider gene therapy for MPS3a.
Unlike Abeona who is relying on inferior intravenous administration of the AAV vector,
Lysogene attempted direct intraparenchymal delivery of their AAV vector. That means they
injected it directly into the patient's brain. By directly introducing the virus into the
brain, any concern that the virus would not reach brain tissue is eliminated. In other
words, the delivery problem has been eliminated. Simply stated, if the direct
approach attempted by Lysogene doesn't work then intravenous gene therapy (i.e.,
Abeona's approach of indirectly applying the treatment that may or may not
successfully reach the brain) clearly doesn't stand a chance, in our view. The results
presented by Lysogene were underwhelming as shown in this abstract which concluded, "
Brain atrophy evaluated by magnetic resonance imaging seemed to be stable in Patients
1 and 3 but tended to increase in Patients 2 and 4." Hardly a ringing endorsement and this
is from a study where the barrier to delivery was non­existent. How well could Abeona's
approach, which has a much more difficult path to delivery, be expected to work in light of
these Lysogene results?


How will Abeona do better than this when they are administering the virus into a
peripheral vein and hoping or praying that it gets into the central nervous system?
We already know that superior delivery via directly into the brain showed mediocre
results at best.


Making matters worse for Abeona is that the study described above used a promoter that
is active in all tissue types. As we'll see below, Abeona's promoter choice is even more
problematic as well which brings us to flaw number 2.


Abeona Flaw #2 ­ The promoter chosen by Abeona doesn't work in glia


The nervous system consists of two broad cell classifications: neurons and glia. Neurons
are the cells that transmit electric signals to other cell types and glial cells play a
supportive role. MPS3a affects both cell types (see electron micrograph in the source
below).



http://www.lysogene.com/

http://online.liebertpub.com/doi/abs/10.1089/hum.2013.238
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 5/38


Source: NCBI


The AAV vector being used by Abeona supposedly transduces both cell types but getting
into the cell is not enough: Once inside the virus must express the protein of interest. If the
virus gets into the correct cells but does not express, there is no benefit to the patient.
Expression of the protein of interest is done by placing a good copy of the gene in front of
a "promoter" which will drive its expression.


Abeona chose a promoter called U1a as shown in their clinical trials.gov listing:


Unfortunately for Abeona, they chose a promoter called U1a that apparently IS NOT
ACTIVE in glia which means it can only treat some of the cells in the CNS. How can one
honestly expect good results from this? Moreover, what does this say about the scientific



https://www.ncbi.nlm.nih.gov/pubmed/10561464

https://clinicaltrials.gov/ct2/show/NCT02716246?term=NCT02716246&rank=1

http://www.nature.com/mt/journal/v11/n1s/full/mt2005974a.html

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId14.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 6/38


acumen of Abeona's scientists? This is a rookie mistake.


Furthermore, Abeona has set the bar for the primary end point for their trial comically low.
Below is Abeona's primary endpoint from clinical trials.gov. How difficult do you think this
primary endpoint ­ development of unacceptable toxicity ­ will be to achieve? I could
develop unacceptable toxicity levels with a rock. Even if Abeona achieves this primary
outcome measure, it's essentially meaningless.


Why would Abeona set the bar so low? And if Abeona wants to run a credible trail, why go
to Nationwide Children's Hospital (aka the place it seems to me that you go if you want a
positive, but worthless, trial) to determine whether the drug works or not? I covered the
dubious science and rampant conflicts of interest that have occurred in other trials at NCH
in my recent report on Avexis (NASDAQ:AVXS): please see that report for further details,
which I believe are also relevant for Abeona.


Abeona Flaw #3: ABEO has no rational regulatory path forward and doesn't appear
serious about creating one best I can tell



https://clinicaltrials.gov/ct2/show/NCT02716246?term=NCT02716246&rank=1

https://seekingalpha.com/symbol/AVXS

https://seekingalpha.com/article/4024171-avexiss-house-cards-dubious-trials-drug-lawsuit-fraud-allegations-strong-sell-94-percent
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 7/38


Let's compare one company (Shire) that is serious about developing a safe and
efficacious drug for patients who have MPS III to a company that does not appear serious:


Shire is conducting an 8 year (!) safety study for its treatment for MPS IIIA: They want to
make sure that their (logical, rational) treatment of replacing the needed enzyme in the
patients is safe and is yielding the desired results. ABEO (through the NCH) conducted a
one year 'natural history' study. Somehow, the NCH was able to get 25 patients in the
study and through a one­year evaluation including spinal taps, MRIs and other
assessments all within an 18­month time period (February 2014 ­ November 2015).


We do not believe that there is anything clinically useful which NCH could have possibly
gleaned from a one­year "natural history" study with just 25 patients that would be relevant
to the FDA. If they had the right endpoints in mind, they would put it in their Phase I/II
protocol. Tellingly, instead ABEO has as their primary endpoint the clearly useless
"development of unacceptable toxicity."


One of their competitors (Lysogene) has gone so far as to say that there are "no validated
surrogate markers" for MPS IIIa. This is extremely important for the 'ABEO is the next
SRPT crowd'. "No validated surrogate markers" means that nothing has been measured
which has been demonstrated to show impact on the disease. We can propose theories
and conduct experiments on mice all day but until someone shows longitudinally (over a
number of years) that lowering or raising something in these kids actually helps them out,
everyone is just guessing. And the FDA has been extraordinarily clear in its first post­
SRPT approval talk they go so far as to say "Sponsor and FDA should agree on the
surrogate [marker] and drug effect considered 'reasonably likely' to predict clinical benefit
before unblinding data." This represents two major problems. First, ABEO has no blinded
data to begin with and ABEO does not appear to me to want to gather any. Second, they
clearly haven't defined these markers with the FDA in advance of their trial otherwise they
would have made *that* their primary endpoint. Instead, the Company is betting that
investors will just take the bait on a single center, uncontrolled clinical trial, like the SRPT
trial (at the NCH no less), which caused a civil war in the FDA.


The bottom line is that, similar to Avexis, Abeona's proposed gene therapy treatment is
deeply flawed:


The delivery mechanism is inferior to existing studies from other companies with
superior delivery mechanisms which still showed mediocre clinical results,
rendering ABEO's science unviable.



https://clinicaltrials.gov/ct2/show/NCT01299727?term=mps+III&rank=5

https://clinicaltrials.gov/ct2/show/NCT02037880?term=mps+III&rank=10

https://www.ncbi.nlm.nih.gov/pubmed/24524415

http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM525805.pdf
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 8/38


The promoter Abeona has chosen doesn't even work in glia anyway, rendering
ABEO's science unviable.


Abeona is attempting to clear a bar that is so low that it's essentially meaningless,
meaning whatever their trial shows should be clinically worthless.


All occurring at what we believe is the most dubious clinical site in the country.


ABEO's Total Addressable Market


MPS type 3a has an incidence of 1 in 128,000 new births and a prevalence of 1 in
114,000 people.


MPS type 3b has an incidence of 1 in 235,000 new births and a prevalence of 1 in
211,000 people.


Source:Jama Network


Assuming 4,000,000 births per year in the US, the total addressable number of patients is
31 per year for MPS 3a and 17 per year for MPS 3b, or 48 total patients in the TAM if
ABEO somehow beat the odds, got approval, and then captured 100% of the market.


As we saw in the Avexis report, the only company with a gene therapy treatment on the
market is QURE. This treatment is currently offered at $1.2 million, and is not selling well.
Similar to AVXS, we give ABEO the benefit of the doubt and assume that it could charge
$1.5 million per treatment if approved, representing a 25% premium to QURE's treatment.
This represents a best case $72 million annual revenue target in theory for both
applications. In reality, the actual potential is clearly much lower.


The 31 patients ($47m of revenue, or 31 x $1.5m) with MPS3a will be divided amongst up
to four companies including Abeona should they all secure approval.


Shire is conducting a study in MPS3a using enzyme replacement therapy administered in
the CSF. Shire's approach guarantees delivery of functional protein. If cells are able to
take up the protein then Shire's approach ­ which introduces vastly more functional
enzyme in the CSF ­ should work better and come to market years sooner.


Lysogene who is conducting long­term follow up of their intraparenchymal gene therapy.
As noted before if this doesn't work, the likelihood that Abeona does is abysmal.



https://jamanetwork.com/journals/jama/fullarticle/188380

https://clinicaltrials.gov/ct2/show/NCT01299727

https://clinicaltrials.gov/ct2/show/NCT02053064?term=mps3a&rank=11
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 9/38


Duke is conducting a study in which mixed chimerism is attempted to restore enzymatic
function. This has the advantage of being a well understood procedure but the
disadvantage of requiring a compatible marrow donor.


And Abeona. The $47 million annual revenue target is pie­in­the­sky. For starters, if
Abeona's treatment proves effective, then Lysogene's will almost certainly prove to be at
least as effective for the reasons shown above (and probably more effective because it's
delivered directly). So at a minimum, we can cut $47 million in half right there, to $23
million. More likely however, is that Lysogene's direct delivery would prove vastly superior
to Abeona's indirect delivery, meaning that most likely Lysogene would eat Abeona's lunch
and take all of the patients. If Shire and Duke are successful, there will be even more
competition.


We believe the true potential revenue of Abeona, even if approved, approximates
zero. But we don't think Abeona will ever get any treatment approved, for the reasons
listed above, and because of the people involved at the company who have a long history
of failure and destroying shareholder value.


The above research shows definitively that ABEO's gene therapy treatments are dead in
the water in our view. We could stop writing now as we have already conclusively
nullified the bull case on ABEO. But the bear case is actually much, much stronger than
this, so we will include all of our findings below.


This concludes the science section of this report. We now turn to the history of the
people involved in Abeona, which is where the real fun begins.


Introducing the Cast of Characters: David Blech and Steven Rouhandeh


David Blech: The Godfather of Biotech Stock Fraud


Many of today's investors are too young or too new to the investment business to
remember the spectacular flame out of D. Blech & Co in the early 1990s. The firm, named
after now­convicted felon David Blech who was a key insider in ABEO (in previous
incarnations), specialized in making investments in low quality biotech stocks. Blech, who
is bipolar and reportedly has a gambling addiction, pled guilty to securities fraud in 1998
but avoided prison time. As recently as 2013, Blech was apparently headed to prison for a
second securities fraud conviction according to the NY Times. Known as an aggressive
stock promoter involved in many dubious companies, "Blech stocks" have long been a
favorite among short sellers and have frequently produced stellar returns for those betting



https://clinicaltrials.gov/ct2/show/NCT01372228?term=mps3a&rank=16

http://www.nytimes.com/2013/09/06/business/david-blech-a-biotech-king-dethroned.html
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 10/38


they will decline in price. Several of these legacy Blech stocks, including Abeona, still exist
in the market, though often only after failing and re­emerging, and/or saddling early
investors with crushing dilution and losses.


Eventually and not that surprisingly, D. Blech & Co. imploded. Sources claim the firm's
collapse caused several biotech stocks to drop by 20­40% or more in a single day, in what
later became known as "Blech Thursday." A Reuters blog identified that these companies
lost more than $168 million in market capitalization on this one trading day alone. To detail
all of the schemes Blech was involved with would require a novel­length report but I
believe Blech's own employees said it best when they claimed that Blech ran "a sleazy
boiler room operation."


We're not aware of anyone within biotech over the last few decades who has a worse
reputation than David Blech ­ and we've looked. His involvement in the predecessor
companies that ultimately became Abeona is an undeniable red flag, in our view.


Steven Rouhandeh: Blech's Protégé and Now Master of Biotech Wipeouts


Abeona's Executive Chairman and largest shareholder via his investment firm SCO
Capital and affiliates is Steven Rouhandeh. ABEO specifically suggests that Rouhandeh's
"extensive domestic and international financial experience in the health care industry" are
his qualifications to serve on the board. So what exactly are Rouhandeh's qualifications?


Early in his career, Rouhandeh worked in a position of authority (Managing Director) at D.
Blech & Co. and apparently didn't leave until nearly the very end, according to the Wall
Street Journal. Since that time, as we will see below, Rouhandeh has blazed a trail of
shareholder destruction in lousy biotech stocks that would rival even Blech himself.


In my opinion, the key take away here is that Rouhandeh worked in a high ranking
position for a biotech stock promoter who was convicted of securities fraud and involved in
manipulating biotech stocks. This is not an impressive qualification and would make any
investor conducting real due diligence at least a little uneasy. I suspect that most Abeona
investors are completely unaware of this fact because it has apparently been omitted from
Rouhandeh's recent, publicly available business background profiles. The key question
now becomes, how and why was this key piece of Rouhandeh's qualifications omitted
from his biography and past?



http://www.wsj.com/articles/SB857944623252857500

http://www.bioworld.com/perspectives/2013/05/03/biotechs-white-knight-aka-serial-cheater-gets-prison-time-finally/

http://www.bioworld.com/perspectives/author/lynnyoffee/

https://www.bamsec.com/filing/114420416093059/1?entity_id=318306&hl=79457:79652&hl_id=eyrx1kdwz

http://www.wsj.com/articles/SB939744994108359066

http://www.bloomberg.com/research/stocks/private/person.asp?personId=5029124&privcapId=360935
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 11/38


Source: Google Images and Institutional Investors Alpha


After reviewing numerous profiles, I found that Rouhandeh's role as Managing Director at
D. Blech & Co. mysteriously disappears even though it seems he previously included it
before the firm was the subject of widespread media coverage based on David Blech's
fraudulent behavior. This complete lack of disclosure is especially unsettling since
Rouhandeh still discloses that he served as a Managing Director at Metzler Bank which he
worked at before he began working at D. Blech & Co. This is consistent across the public
business profiles I reviewed, it does not appear to be an administrative error. It's worth re­
iterating that these actions are highly relevant to someone making a decision to invest in a
biotech company and I find it appalling that these proper disclosures have been neglected.


The History of Steven Rouhandeh and SCO Capital


SCO Capital is ABEO's largest shareholder, beneficially owning more than 40% of the
shares outstanding as of October 25, 2016. According to Bloomberg, Steven H.
Rouhandeh is the Chairman and Founder of SCO Capital. SCO Capital is a private equity
and venture capital firm specializing in PIPE investments primarily in biotechnology,
healthcare, pharmaceuticals, and life science sectors. Rouhandeh has served as the Chief
Investment Officer of SCO Capital since 1997.


Given that SCO Capital is ABEO's largest shareholder and ABEO's current Executive
Chairman is Rouhandeh, it's worth conducting comprehensive and professional due
diligence on Rouhandeh and more specifically his history to develop a thorough



https://static01.nyt.com/images/2013/09/06/business/SUBINSIDER/SUBINSIDER-master675.jpg

http://www.institutionalinvestorsalpha.com/PDF/691/AIN020209.pdf

https://www.bamsec.com/filing/90311297000488/1?entity_id=919745&hl=61611:61709&hl_id=e1pdgjowz

https://www.bamsec.com/filing/31830610000039/1?entity_id=318306&hl=112890:112991&hl_id=4y62gsozg

https://www.bamsec.com/filing/90311297000488/1?entity_id=919745&hl=61711:61812&hl_id=vym5wiubz

https://www.bamsec.com/filing/114420416093059/1?entity_id=318306&hl=38901:39093&hl_id=nkql6wb7m

https://www.bamsec.com/filing/114420416130254/1?entity_id=318306&hl=56071:56076&hl_id=ejakpv_wm

http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=4996112

http://www.bloomberg.com/research/stocks/people/person.asp?personId=5029124&privcapId=360935

https://www.bamsec.com/filing/114420416134339/1?entity_id=318306&hl=50871:50890&hl_id=vyn_zdowf

https://static.seekingalpha.com/uploads/2016/12/10/40228756-14814150186926389_origin.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 12/38


understanding of the individual that apparently controls such a large portion of ABEO. In
fact, ABEO discloses that the company is "highly dependent" on the efforts of Rouhandeh
and other senior management.


Apparently, Rouhandeh is so valuable to ABEO that the company paid him over $4 million
in compensation for 2014 and 2015 combined:


Source: Proxy Statement


Notice that Rouhandeh is the highest paid individual shown in the compensation table
even though that distinction would typically belong to the CEO at most companies. I would
also note that this amount of compensation is virtually unheard of for an Executive
Chairman of a small cap company that continually loses money. Investors might be
surprised to learn that Rouhandeh's total compensation over that time frame approximates
the total amount of research and development spending by ABEO. This is a huge red flag
for a preclinical biotech company:


Source: Annual Report


Rouhandeh Ran a Website That Promoted Lousy Micro Cap Penny Stocks



https://www.bamsec.com/filing/114420416091600/1?entity_id=318306&hl=88904:89132&hl_id=vy7sgu_zg

https://www.bamsec.com/filing/114420416093059/1?entity_id=318306&table=56

https://www.bamsec.com/filing/114420416091600/1?entity_id=318306&table=67

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId44.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId46.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 13/38


In the 1990s, Rouhandeh ran a website called SmallCapsOnline that apparently led the
WSJ to start asking questions about its operations. The Wall Street Journal uncovered
that the website smallcapsonline.com was actually a registered investment advisor. The
WSJ claimed that 8 of 31 companies recommended on the website paid an affiliated
company, Bridge Technology Group (BTG), for investment banking and investor relations
services. BTG is the closely held parent company of SmallCapsOnline. This seems like
obviously a huge conflict of interest if proper disclosures required by regulators were not
followed.


Reviewing archived versions of SmallCapsOnline showed that the website frequently
featured a collection of biotech/healthcare penny stocks. Even more disturbing was the
fact that Steven Rouhandeh was not the only ABEO insider involved with the website.


Archived records show that Small Caps Online and their affiliated entities were run by a
tight knit group of individuals who had been working together for what appears to be
years. Disclosures found buried in ABEO's SEC filings show that the following ABEO
insiders were employed by SCO and/or their affiliates:


"Mr. DiPietro is an employee of SCO Securities LLC."


"Mr. Tsao is an employee of SCO Securities LLC."


"Mr. Davis is an employee of SCO Securities LLC."


"Mr. Alvino is an employee of SCO Securities LLC."


Source: ABEO Shelf Registration


SCO Insiders & Affiliates


ABEO Insider Role(s) @ ABEO Role Entity


Steven H.


Rouhandeh


Director and Chairman of the


Board


Chief Investment


Officer


SCO Capital


Partners, L.P.


Steven H.


Rouhandeh


Director and Chairman of the


Board


Founder SCO Financial Group


LLC


Steven H.


Rouhandeh


Director and Chairman of the


Board


Chairman SCO Securities LLC



http://www.wsj.com/articles/SB939744994108359066

https://www.bamsec.com/filing/31830604000007/1?entity_id=318306&hl=54948:55116&hl_id=vjkpea8gz

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=36832:36917&hl_id=4jzel73mg

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=36918:37018&hl_id=n178wybzz

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=36832:36917&hl_id=4jzel73mg

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=37019:37220&hl_id=vjyf-yrfg

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=36832:36917&hl_id=4jzel73mg

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=71220:71340&hl_id=vjovmyhgm
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 14/38


Steven H.


Rouhandeh


Director and Chairman of the


Board


Chairman SCO Capital Partners


LLC


Steven H.


Rouhandeh


Director and Chairman of the


Board


Managing Member Beach Capital LLC


Mark J. Alvino Director Managing Director SCO Financial Group


LLC


Mark J. Alvino Director Employee SCO Securities LLC


Jeffery B. Davis Former CEO and Chairman of


the Board


President SCO Securities LLC


Jeffery B. Davis Former CEO and Chairman of


the Board


Executive SCO Capital Partners


LLC


Preston Tsao Director Employee SCO Securities LLC


Jeffery B. Davis Former CEO and Chairman of


the Board


Managing Member Lake End Capital LLC


Howard S.


Fischer


Director at MacroChem Managing Director SCO Securities LLC


Christine


Silverstein


Vice President, Investor


Relations


Managing Director SCO Financial Group


Source: Public Information, Sources Directly Linked


These individuals were heavily involved with either the promotion of ABEO through
SmallCapsOnline or directly involved with ABEO itself, and in some cases both.


SmallCapsOnline even featured research reports that touted an obscure OTC listed penny
stock called Access Pharmaceuticals which failed and later became a part of ABEO.



https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=36832:36917&hl_id=4jzel73mg

https://www.bamsec.com/filing/95013605008393/1?entity_id=743884&hl=20174:20499&hl_id=nj3p1qsgz

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=36832:36917&hl_id=4jzel73mg

https://www.bamsec.com/filing/157104915004582/1?entity_id=318306&hl=40860:40877&hl_id=e1ddiauzm

https://www.bamsec.com/filing/31830610000039/1?entity_id=318306&hl=13427:13474&hl_id=4krrpxnmm

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=40089:40177&hl_id=4ypmffrmg

https://www.bamsec.com/filing/31830610000039/1?entity_id=318306&hl=13427:13474&hl_id=4krrpxnmm

https://www.bamsec.com/filing/31830604000007/1?entity_id=318306&hl=55999:56294&hl_id=njmm-almg

https://www.bamsec.com/filing/31830608000007/1?entity_id=318306&hl=6065:6152&hl_id=vyh9-rlfz

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=72325:72436&hl_id=njkazybgf

https://www.bamsec.com/filing/31830608000007/1?entity_id=318306&hl=6065:6152&hl_id=vyh9-rlfz

https://www.bamsec.com/filing/31830608000020/1?entity_id=318306&hl=77822:77882&hl_id=ekx7xkrmg

https://www.bamsec.com/filing/31830600000007/1?entity_id=318306&hl=24653:24695&hl_id=vj67nqhzf

https://www.bamsec.com/filing/31830604000007/1?entity_id=318306&hl=55423:55706&hl_id=4jp0l0imm

https://www.bamsec.com/filing/31830608000007/1?entity_id=318306&hl=6065:6152&hl_id=vyh9-rlfz

https://www.bamsec.com/filing/31830608000007/1?entity_id=318306&hl=6517:6590&hl_id=vyhzgr8zz

https://www.bamsec.com/filing/74388406000034/1?entity_id=743884&hl=259622:259751&hl_id=v1ftp08fz

https://www.bamsec.com/filing/74388406000034/1?entity_id=743884&hl=259622:260106&hl_id=vjnydcumf

https://www.bamsec.com/filing/114420416133030/2?entity_id=318306&hl=6036:6123&hl_id=ekolmj_fg

http://www.sbwire.com/press-releases/abeona-therapeutics-appoints-christine-silverstein-as-vice-president-of-investor-relations-686553.htm
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 15/38


If we look into other Rouhandeh affiliated entities we find that an interesting pattern
develops that I believe truly shows what Rouhandeh is up to. When reviewing
Rouhandeh's long career on Wall Street we find that he has somehow managed to involve
himself in a portfolio of some of the lowest quality companies including penny stocks,
bankruptcies, and outright failures.


ABEO's 20 Year History: Crummy Reverse Merger Penny Stock with Ties to Insiders
Convicted of Fraud


As we will see shortly, Abeona is essentially a failed rollup of Blech and Rouhandeh
investments that each collapsed, only to be rebooted several times in a history that goes
back over 20 years. Let that sink in: Abeona is the end product of a more than 20­
year history of failure and shareholder value destruction that has ties directly to a
convicted felon who served jail time for biotech securities fraud. Only microcap
penny stocks allow this type of failure, principally because most investors don't
read the filings.


This section of the report is potentially confusing given the extensive and pervasive asset
shuffling that occurred to get Abeona to where it is today. I recommend readers print this
section out and study it carefully.


ABEO's predecessor was originally founded in 1974 and at the time was known as
Chemex. It appears that Chemex ultimately failed as evidenced by its reorganization and
reverse merger with Access Pharmaceuticals which became ABEO. Later, Access
Pharmaceuticals apparently hired David Blech as a consultant and paid him$480,000 in
compensation as well as warrants to purchase 600,000 shares of common stock. Blech
also appears to have been a financial consultant for what is now ABEO all the way back to
1990 when it was still known as Chemex. David Blech and/or his affiliates eventually
acquired a significantly large stake in what was to become ABEO:


Source: SEC Filing



https://www.bamsec.com/filing/31830697000003/1?entity_id=318306&hl=3369:3563&hl_id=vjm7we3gf

https://www.bamsec.com/filing/95014696000501/1?entity_id=318306&hl=108625:109072&hl_id=njnpy6azm

https://www.bamsec.com/filing/95014696000501/1?entity_id=318306&hl=175616:175635&hl_id=4kwsyp0zg

https://www.bamsec.com/filing/95014696000501/1?entity_id=318306&hl=178001:178556&hl_id=nyhhnenzm

https://www.bamsec.com/filing/95013595002693/1?entity_id=318306&hl=372830:373256&hl_id=nycaun3zm

https://www.bamsec.com/filing/95013496003575/1?entity_id=318306&hl=148343:148374&hl_id=ejg7jvhzf

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId81.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 16/38


In 1996, Blech and/or his affiliates (highlighted below) sold or attempted to sell millions of
shares of stock:


Source: SEC Filings


What we find even more alarming than Blech's involvement, is that Rouhandeh's website
was promoting ABEO's predecessors and telling investors to BUY shares while Blech and
his affiliates were apparently selling or attempting to sell stock in the late 1990's.
Remember that Rouhandeh previously worked for Blech just a few years prior to these
events. We at Mako Research strongly believe this should not be interpreted as a
coincidence given that Blech was a convicted fraudster and pled guilty to manipulating at
least two biotech stocks.


Below is a screenshot from an archived webpage that shows SCO promoting Access (now
ABEO) shares:


Source: SCOGroup.com



https://www.bamsec.com/filing/95013496003575/1?entity_id=318306&hl=154191:154219&hl_id=vkkhjv3mz

https://www.bamsec.com/filing/31830698000009/1?entity_id=318306&hl=161329:161428&hl_id=4kusr0j7z

https://www.bamsec.com/filing/31830600000011/1?entity_id=318306&hl=48684:48835&hl_id=ekmg1r3fg

http://www.nytimes.com/2013/09/06/business/david-blech-a-biotech-king-dethroned.html

https://web.archive.org/web/20020523204018/http:/www.scogroup.com/

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId83.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId88.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 17/38


In a 9 page research report penned in 1998, Small Caps Online deemed the shares
"undervalued" and "lower risk" assigning a "current fair value to be in the range of $10 to
$15 per share". It appears this wasn't the only time Small Caps Online or Bridge
Technology Group peddled Access Pharmaceuticals shares in glowing reports. Internet
message boards apparently show that SCO/Bridge published research on the company
no less than 4 times. Evidence of these reports can be viewed here, here, here, here, and
here. We do not have copies of the original press releases but we personally believe
these to be accurate copies based on the format in which they have been posted: you can
reach your own conclusion. In all cases, following the advice detailed in these research
reports would have resulted in devastating losses of value. Below is a table of the losses
investors would have experienced if they had purchased shares based on the dates
SCO/Bridge made recommendations:


Source: Capital IQ & Silicon Investor


According to the market, Access Pharmaceuticals shares weren't undervalued at all and
appear to have been extremely overvalued as they ended up experiencing substantial
price declines. In fact, we could not find any research published by Small Caps Online or
Bridge Technology that told investors to outright sell their shares despite these price
outcomes, which played out over an extended time period. The table above clearly shows
that SCO/Bridge/Rouhandeh or whoever was running the website at that point promoted
Access Pharmaceuticals no less than 5 times AFTER Blech and his affiliates had acquired
a significant position in the stock.


This begs the question: Was Rouhandeh effectively running a website that touted Access
(now ABEO) as a BUY so that Blech could sell his large position into artificially inflated
prices? It's difficult to pinpoint exactly what was going on but one thing we know for sure is
that this paper trail led ABEO to its current form and that Rouhandeh appears to be one of
the common characters behind the evolution.



http://www.siliconinvestor.com/readmsg.aspx?msgid=8123290

http://www.siliconinvestor.com/readmsg.aspx?msgid=12557985

http://www.siliconinvestor.com/readmsg.aspx?msgid=10884721

http://www.siliconinvestor.com/readmsg.aspx?msgid=7235181

http://www.siliconinvestor.com/readmsg.aspx?msgid=6178538

https://static.seekingalpha.com/uploads/2016/12/10/40228756-14814137005990393_origin.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 18/38


Rouhandeh & ABEO Insiders at the Epicenter of Biotech Blowups: "The ABEO
Pattern"


An in depth review of Rouhandeh's past involvements revealed an alarming pattern of
repeated shareholder value destruction that appeared to have predictive outcomes. One
of the common themes that emerged was that Rouhandeh and his affiliates (including
current and former ABEO insiders in some cases), would take large positions in low
quality penny stocks that would eventually end up losing a significant amount of value. We
believe that these events parallel what is currently happening at ABEO and that the future
of ABEO will be similar to these prior efforts.


In 2003, SCO Capital Partners LLC acquired over 30% of Enhance Biotech, Inc.
(OTC:EBOI) shares. Soon after, the company agreed to pay SCO Financial Group$9,000
per month ($108,000 per year) for "investment and advisory services" followed by a one­
time retainer fee of$25,000 for similar services in 2004. Below are some of the events that
occurred at Enhance Biotech, Inc. that show a striking similarity to events that have
occurred at ABEO (more on this later):


Enhance Biotech's auditors warned investors no less than 5 times (here, here, here,
here, and here) that the company might fail due to its financial condition.
Enhance Biotech dramatically diluted shareholders starting with 1,612,900 shares in
2002 and ending with 55,627,931 shares in 2005.
Enhance Biotech had racked up millions of dollars in losses totaling at least$41.2
million by our estimates.
Enhance Biotech was a reverse merger.
Enhance Biotech defaulted.


With these kinds of events occurring over a relatively short period of time, only one
outcome is likely and eventually the stock price collapsed:



https://www.bamsec.com/filing/95013604001807/1?cik=1124077

https://www.bamsec.com/filing/95013604001807/1?entity_id=1124077&hl=5351:5356&hl_id=41npavdgz

https://seekingalpha.com/symbol/EBOI

https://www.bamsec.com/filing/117091803000475/1?entity_id=1124077&hl=23095:23372&hl_id=4jst1bdgg

https://www.bamsec.com/filing/117091803000475/1?entity_id=1124077&hl=23239:23255&hl_id=eypujsuzg

https://www.bamsec.com/filing/114420405008734/1?entity_id=1124077&hl=52411:52419&hl_id=eyfdxh_gz

https://www.bamsec.com/filing/114420405020689/1?entity_id=1124077&hl=167620:168107&hl_id=n1wzgbomf

https://www.bamsec.com/filing/114420405020689/1?entity_id=1124077&hl=167620:168107&hl_id=n1wzgbomf

https://www.bamsec.com/filing/114420404009251/1?entity_id=1124077&hl=60631:61303&hl_id=4k5qzbdmg

https://www.bamsec.com/filing/117091803000678/1?entity_id=1124077&hl=21454:21831&hl_id=nycngsdgf

https://www.bamsec.com/filing/117091802000034/1?entity_id=1124077&hl=40771:41129&hl_id=n118fb_ff

https://www.bamsec.com/filing/112407701500008/1?entity_id=1124077&hl=41831:42199&hl_id=ek_lgbugg

https://www.bamsec.com/filing/117091802000034/1?entity_id=1124077&hl=3238:3313&hl_id=nk3dqsdgf

https://www.bamsec.com/filing/114420405020689/1?entity_id=1124077&hl=3151:3231&hl_id=njbcqbdzg

https://www.bamsec.com/filing/114420405020689/1?entity_id=1124077&hl=87878:88024&hl_id=njfg4sogg

https://www.bamsec.com/filing/112407701500005/1?entity_id=1124077&hl=118550:118720&hl_id=4yp9gkkmm

https://www.bamsec.com/filing/114420405020689/1?entity_id=1124077&hl=200975:201010&hl_id=nkl0fkkgg
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 19/38


Source: Capital IQ


The chart shows what a disaster this was but perhaps the situation at Enhance Biotech
was an isolated event? It turns out that it doesn't appear to be an isolated event and that
Rouhandeh and the SCO team had been involved in two other penny stock failures that
are intimate to the ABEO story. Pay close attention.


The MacroChem Wipeout


In 2006, SCO Capital acquired a majority stake in MacroChem Corporation
(NasdaqGM:MACM) and controlled nearly 80% of the shares outstanding:


Source: MacroChem SEC Filings



https://www.bamsec.com/filing/74388406000002/1?entity_id=743884&hl=36413:36491&hl_id=ejv3nhm7g

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId116.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId118.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 20/38


Following this, SCO Capital Partners designated Davis, Fischer, and Alvino to the Board
of Directors, all of them SCO insiders. Jeffrey Davis' involvement is particularly important
because he is ABEO's former CEO, current Chief Operating Officer, and served as the
President of SCO Securities. Essentially, what we are trying to point out is that Jeffrey
Davis was in the thick of it with Rouhandeh, and played a key role at ABEO as well.


Similar to Blech, Rouhandeh somehow convinced (or forced?) MacroChem to pay SCO
Securities LLC $12,500 per month ($150,000 per year) for financial advisory services.
Additionally, MacroChem paid SCO Securities LLC $577,850 and 6 year warrants to
purchase 786,189 shares of common stock at an exercise price of $1.05 per share. It's
unclear what benefit these payments provided shareholders but we can't help but see this
as a direct parallel to the consulting agreements Blech entered into with Chemex and
Access.


Either way, MacroChem ended up experiencing a series of events that seemingly led the
company to a collapse in its share price:


MacroChem's auditors warned investors no less than 4 times (here, here, here, and
here) that the company might fail due to financial conditions.
MacroChem's shareholders experienced substantial dilution starting with 3,680,875
shares in 2007 and ending with 45,837,547 shares in 2008.
MacroChem had accumulated over $100 million in losses.
MacroChem had engaged in a series of related party transactions with SCO and/or its
affiliates.
MacroChem received a delisting notice from Nasdaq and was determined to be a "
public shell" by regulatory authorities.
MacroChem goose egged the revenue line for 4 years.
MacroChem was an OTC listed penny stock, trading at $0.30 per share.


Taken together, these events are not the hallmarks of a successful biotech company nor
are they a mere coincidence, in our view. Eventually MacroChem's stock found its way to
fair value as investors realized that MacroChem was not going to live up to all the hype:



https://www.bamsec.com/filing/110465908027880/1?entity_id=743884&hl=74771:74897&hl_id=vy7zukpgm

https://www.bamsec.com/filing/110465908027880/1?entity_id=743884&hl=75678:75807&hl_id=ej6gd1wgz

https://www.bamsec.com/filing/110465908027880/1?entity_id=743884&hl=75988:76096&hl_id=4jfqdjvmm

https://www.bamsec.com/filing/114420416091600/1?entity_id=318306&hl=117757:117798&hl_id=ny1wjsgmm

https://www.bamsec.com/filing/114420416091600/1?entity_id=318306&hl=117633:117688&hl_id=n1n1jsz7f

https://www.bamsec.com/filing/74388406000034/1?entity_id=743884&hl=257735:257942&hl_id=vyuq_cuzz

https://www.bamsec.com/filing/74388406000034/1?entity_id=743884&hl=257943:258183&hl_id=vjmtuypgf

https://www.bamsec.com/filing/74388405000017/1?entity_id=743884&hl=121266:121740&hl_id=nj6363m7g

https://www.bamsec.com/filing/74388406000034/1?entity_id=743884&hl=133882:134378&hl_id=vya6tngmm

https://www.bamsec.com/filing/74388407000031/1?entity_id=743884&hl=139813:140309&hl_id=4y_r6hg7g

https://www.bamsec.com/filing/74388408000007/1?entity_id=743884&hl=298152:298755&hl_id=v1l1r2f7z

https://www.bamsec.com/filing/110465908071827/1?entity_id=743884&hl=13890:13899&hl_id=4ywyltzmf

https://www.bamsec.com/filing/110465908071827/1?entity_id=743884&hl=13861:13871&hl_id=4jbsxafqm

https://www.bamsec.com/filing/110465908071827/1?entity_id=743884&hl=8005:8027&hl_id=n12wgpm7m

https://www.bamsec.com/filing/74388407000097/1?entity_id=743884&hl=238098:241322&hl_id=vkenwpfmz

https://www.bamsec.com/filing/74388405000065/1?entity_id=743884&hl=2695:2961&hl_id=4jr3b6zmg

https://www.bamsec.com/filing/74388405000058/1?entity_id=743884&hl=3101:3241&hl_id=eksqf6m7m

https://www.bamsec.com/filing/74388408000007/1?entity_id=743884&hl=189015:190432&hl_id=4k8gu6gmz

https://www.bamsec.com/filing/74388407000062/2?entity_id=743884&hl=811:846&hl_id=n1ti8amqm

https://www.bamsec.com/filing/74388408000007/1?entity_id=743884&hl=136536:136623&hl_id=n1q-ptzxm
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 21/38


Source: Capital IQ


It's unclear why Rouhandeh thought that MacroChem would be a good investment but
what we do know is that SCO controlled a substantial portion of the company and had its
crew on the board. This begs the question: was this just a bad investment by Rouhandeh
and his squad or is this part of a broader pattern of the way that SCO conducts business?
Let's find out…


The Somanta Saga


In 2006, SCO Capital Partners LLC was reported to be the largest shareholder of
Somanta Pharmaceuticals, Inc. (OTCPK:SMPM). A 13D filing disclosed that SCO had
acquired over 50% of the company. Somanta disclosed that it had paid SCO a $100,000
"agent fee". In the same filings, Somanta disclosed it had accrued a $474,105 fee payable
to SCO. In 2007, Somanta disclosed that it had agreed to pay SCO a monthly fee of
$12,500 ($150,000 per year) for financial advisory services. Is anyone noticing a pattern
here regarding SCO's large ownership and the fees they receive?


Similar to MacroChem, Somanta Pharmaceuticals, Inc. (OTCPK:SMPM) experienced a
series of events that appear to have been integral, at least in part, to its remarkable
collapse:


Somanta's auditors warned investors no less than two times ( here and here) that the
company might fail due to its financial condition.
Somanta engaged in related party transactions with SCO and/or its affiliates.
Somanta was an OTC listed penny stock.
Somanta had accumulated millions of dollars of losses.
Somanta's subsidiary was subject to legal proceedings.



https://www.bamsec.com/filing/119312506250520/1?entity_id=888671&hl=51680:51747&hl_id=e1rglkkgz

https://www.bamsec.com/filing/95013606000868/1?entity_id=888671&hl=3906:3911&hl_id=4kkoiffgz

https://www.bamsec.com/filing/119312506149226/1?entity_id=888671&hl=153980:154050&hl_id=4knavkfzm

https://www.bamsec.com/filing/119312506149226/1?entity_id=888671&hl=217065:217088&hl_id=4kgldyyzg

https://www.bamsec.com/filing/101905607001329/1?entity_id=888671&hl=361870:362102&hl_id=nj37dtffz

https://www.bamsec.com/filing/101905607000640/1?entity_id=888671&hl=114867:115362&hl_id=ek1qii5gm

https://www.bamsec.com/filing/119312506149226/1?entity_id=888671&hl=79137:79298&hl_id=ekjnoocgf

https://www.bamsec.com/filing/101905607001329/1?entity_id=888671&hl=385764:385790&hl_id=ejndwfyzz

https://www.bamsec.com/filing/119312506169671/1?entity_id=888671&hl=63982:64069&hl_id=nyp0kfymm

https://www.bamsec.com/filing/101905607001329/1?entity_id=888671&hl=35152:35219&hl_id=e1l-sttmg

https://www.bamsec.com/filing/101905607000640/1?entity_id=888671&hl=75539:75565&hl_id=nkyrsftzz

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId139.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 22/38


ABEO insider Jeffrey Davis served as a Director of the company and somehow ended
up owning over 10% of Somanta.


By 2007, SCO and/or its affiliates had obtained a 65% ownership. Again, it's hard to
pinpoint what exactly caused this to be such a disaster but the chart below shows that
investors would have lost nearly everything by the time it was all said and done:


Source: Capital IQ


To be honest, we're not really sure what's going on here besides the fact that it looks like a
small child drew this chart with an Etch­A­Sketch. Liquidity nightmares aside, the stock
price was severely disrespected in a short period of time.


To summarize some of the patterns that appear to be obvious so far:


SCO has a history of making large investments in questionable penny stocks. SCO has a
history of then designating its affiliates to be insiders at these companies. SCO and/or its
affiliates often receive excessive compensation for various services. The investments
discussed above (Enhance, MacroChem, and Somanta) turned out to be horrible based
on the collapses of their stock prices.


We know there has got to be at least one ABEO bull out there saying, "So what, that's like,
a long time ago man, things change, and ABEO is totally a different company than
MacroChem and Somanta."


Wrong. These two lousy penny stocks ended up becoming subsidiaries of ABEO. Once
again shareholders have developed a serious case of amnesia and left SCO/Rouhandeh
at the helm (with their large ownership) for round 3 of a stock story we all know too well at
this point:



https://www.bamsec.com/filing/101905607000640/1?entity_id=888671&hl=344166:344179&hl_id=ejy42kfzm

https://www.bamsec.com/filing/101905607000640/1?entity_id=888671&hl=352784:352879&hl_id=v112rkfmm

https://www.bamsec.com/filing/101905607000640/1?entity_id=888671&hl=353713:353817&hl_id=4kojtyfmg

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId154.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 23/38


We at Mako Research strongly believe that this is NOT a case of "3 rd times a charm"
although we do expect ABEO bulls to attempt to pivot to this desperate long thesis once
they are able to comprehend the findings in this report. As sad as it is, this time will be
different rhetoric is about the only thing left for the bulls to hang their hat on.


Where Did All the Cash Go? The Paper Trail Behind the Abeona Disaster:


Abeona has been nothing short of remarkable as what appears to be a bottomless pit of
cash burn and value destruction:


Source: Capital IQ and our Estimates


Abeona has lost over $325 million since 2006 and the cash burn has accelerated in recent
years. So where did it all go?


It appears this $325m of shareholder cash lost didn't all go to R&D spending as the
cumulative R&D since 1996 was less than $60 million by our estimates, which is only
slightly more than 15% of the total loss.



https://static.seekingalpha.com/uploads/2016/12/10/40228756-14814139499296873_origin.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId155.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 24/38


Source: Capital IQ and our Estimates


Combing through ABEO's SEC filings reveals that, just in the clearly disclosed payments
alone, millions of dollars have been shuffled into the hands of SCO and its affiliates:


Source: SEC Filings:Link, Link, Link, Link, Link, Link, Link, Link, Link, Link, Link, Link


Why is Abeona paying its largest shareholder, who is arguably in a controlling position
within the company given his 40% ownership, and who's founder sits on the board,
millions of dollars for investor relations? This appears as absurd as it is unethical, in our



https://www.bamsec.com/filing/114420415020126/1?entity_id=318306&hl=246835:246931&hl_id=ekg1n2rzg

https://www.bamsec.com/filing/114420415020126/1?entity_id=318306&hl=246835:246931&hl_id=ekg1n2rzg

https://www.bamsec.com/filing/31830614000006/1?entity_id=318306&hl=181928:182023&hl_id=n1fb2nhzf

https://www.bamsec.com/filing/31830613000004/1?entity_id=318306&hl=186645:186740&hl_id=n14whhbgm

https://www.bamsec.com/filing/31830612000020/1?entity_id=318306&hl=185739:185834&hl_id=nkhdh3hfg

https://www.bamsec.com/filing/31830611000002/1?entity_id=318306&hl=187058:187156&hl_id=4y1ltnrff

https://www.bamsec.com/filing/31830610000018/1?entity_id=318306&hl=274730:274856&hl_id=ejl5phbgg

https://www.bamsec.com/filing/31830610000018/1?entity_id=318306&hl=274536:274653&hl_id=vjisahhgm

https://www.bamsec.com/filing/31830608000009/1?entity_id=318306&hl=8146:8441&hl_id=njdoinbgg

https://www.bamsec.com/filing/31830608000009/1?entity_id=318306&hl=8146:8441&hl_id=njdoinbgg

https://www.bamsec.com/filing/31830608000009/1?entity_id=318306&hl=8442:8620&hl_id=ekhki2szm

https://www.bamsec.com/filing/31830608000009/1?entity_id=318306&hl=8442:8620&hl_id=ekhki2szm

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId156.png

https://static.seekingalpha.com/uploads/2016/12/10/40228756-14814140636946123_origin.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 25/38


opinion.


We looked back and could not find a single important scientific discovery in the entire
history of Abeona, despite the >$325 million of losses, which begs several important
questions:


Why does this company need investor relations? They don't do much, if anything, of any
importance, as far as we can tell. Abeona could cease to exist overnight and we doubt
anyone in the medical community would notice or particularly care. Why is Abeona, above
all else, apparently characterized by related party transactions? What has SCO Capital
done to deserve the millions of dollars in fees it has garnered through its involvement at
Abeona? Why do shareholders tolerate this?


Now that we know where over $3 million of the cash went, what about the rest? Estimated
ABEO insider compensation has exceeded $34 million since the data has been tracked by
Capital IQ. Truthfully, we believe this number is understated as ABEO's history dates back
much further, but regardless this is truly a staggering amount of compensation for a small
company this size:


Source: Capital IQ and our Estimates


Finally, in what appears to us another blatant money grab by ABEO insiders, we see that
somehow Rouhandeh was issued shares of ABEO stock that were estimated to be worth
over $4 million as the stock recently eclipsed $8 per share:


Source: SCO Capital 13D Filing



https://www.bamsec.com/filing/157104915004582/1?entity_id=318306&hl=28859:29072&hl_id=n1vqst8ff

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId169.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId170.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 26/38


It's unclear what Rouhandeh did to earn this kind of potential payout, especially since
ABEO has been a seemingly infinite echo chamber of failures for the past two decades.
Wouldn't it make more sense if ABEO waited to pay insiders until AFTER they had
achieved anything of commercial success? As far as we can tell, owning ABEO stock is
tantamount to simply giving your money to insiders: You get the dilution, they keep the
cash. Our only question is: Are they hiring?


ABEO's Decade Long History of Stock Promotion


We've already discussed some of the seemingly promotional behavior and efforts of
ABEO insiders during the SmallCapsOnline days, but what we haven't discussed are
some of the more current involvements in promoting ABEO.


ABEO is no stranger to appearing in YouTube videos promoting the company (and
apparently avoiding nearly all discussions of past failures and decades dilly dallying), you
can view several of them here, here, here, and here. Despite seemingly vigorous efforts to
reach wide audiences, these videos only attract a few hundred views but one video we
watched was particularly insightful as to identifying who might be leading the charge in
ABEO's parabolic stock price as of late.


Source: YouTube


JV Public Relations was founded by Janet Vasquez, who for 10 years worked at IRG (also
known as the "The Investor Relations Group") according to the JV Public Relations
website. We at Mako Research are very familiar with IRG and their involvement in low
quality companies but what we didn't expect to find was that while at IRG, Janet Vasquez's
name appears as the PR contact for Sunsi Energy which eventually became ForceField
Energy Inc. (NASDAQ:FNRG). Based on publicly available documents that we reviewed,
we have no reason to believe these are two different people.


For those unfamiliar with ForceField Energy Inc. , prosecutors charged insiders with
securities fraud, conspiracies to commit securities fraud, wire fraud, and money
laundering. Below are some headlines from credible news sources that covered one of the
most egregious penny stock frauds we've ever had the chance to witness:



https://www.youtube.com/watch?v=KYNgpY8YJaE

https://www.youtube.com/watch?v=ngFXBMb10Do

https://www.youtube.com/watch?v=RqZGWiBSWu8

https://www.youtube.com/watch?v=kXevieE88KM

https://www.youtube.com/watch?v=vDluJNN7OoE

http://www.jvpublicrelationsny.com/who_we_are

http://www.jvpublicrelationsny.com/who_we_are

http://www.forcefieldenergy.com/SunSi_NASDAQ_release.pdf

https://seekingalpha.com/symbol/FNRG

http://www.reuters.com/article/us-forcefield-charges-idUSKCN0XU22D

http://www.reuters.com/article/us-forcefield-charges-idUSKCN0XU22D

http://www.reuters.com/article/us-forcefield-charges-idUSKCN0XU22D

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId176.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 27/38


Source: Reuters & Bloomberg


Reuters goes on to report the following, which we believe is particularly important given
Janet Vasquez's history with FNRG:


"The charges against the defendants, who include stock promoters, brokers and investor
relations officials…"(Emphasis ours)


Further it was explained what the defendants had done:


"took a company with essentially no business operations and little revenue and
deceived the market and their clients into believing it was worth hundreds of millions
of dollars through a dizzying round of unauthorized trades and deceptive
promotions,"… " The deceived investors were left holding the empty bag."
(Emphasis ours)


Not surprisingly, FNRG was halted by regulators, catching investors completely off guard.
Below you can see just how freely the shares fell once the truth was out:


Source: Capital IQ


To be clear, Janet Vasquez was listed as a PR Contact for FNRG but it's unclear what
involvement she had directly or indirectly relating to these matters. What we do know is
that Janet Vasquez's firm, JV Public Relations, proudly presents these companies as
clients on the firm's website:



http://www.reuters.com/article/us-forcefield-charges-idUSKCN0XU22D

https://www.bloomberg.com/news/articles/2015-04-20/forcefield-energy-ex-chairman-said-to-be-charged-in-conspiracy

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId184.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId187.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 28/38


Source: JV Public Relations & Capital IQ with our estimates


We can speculate as to what's really going on here but we encourage everyone to do their
own due diligence and come to their own conclusions.


While we're on the subject of Investor Relations, we also discovered that in 2016 Abeona
appointed Christine Silverstein as Vice President, Investor Relations. What's perhaps
most interesting about Silverstein, besides that fact that she was a finalist on Fox's
MasterChef television series, is that she also served as a Managing Director of SCO
Financial Group. Silverstein's LinkedIn profile reveals that she too had previously worked
at IRG and to bring this full circle… Christine appears to have served as the Investor
Relations contact for none other than MacroChem. Note: Christine Silverstein's LinkedIn
shows in parenthesis what we believe to be her maiden name.


Source: MacroChem SEC Filing and LinkedIn


What's truly sad about this whole situation is that retail investors are often the victims
because they are easily fooled by the type of shenanigans that occur in small cap biotech
stocks. As it turns out retail investors appear to be one of Christine's main targets:



http://www.jvpublicrelationsny.com/clients

http://www.marketwired.com/press-release/abeona-therapeutics-appoints-christine-silverstein-as-vice-president-investor-relations-nasdaq-abeo-2120697.htm

http://www.marketwired.com/press-release/abeona-therapeutics-appoints-christine-silverstein-as-vice-president-investor-relations-nasdaq-abeo-2120697.htm

https://www.sec.gov/Archives/edgar/data/743884/000074388407000064/ex99_1pressrel.htm

https://www.sec.gov/Archives/edgar/data/743884/000074388407000064/ex99_1pressrel.htm

https://www.linkedin.com/in/christineberni1

http://www.marketwired.com/press-release/abeona-therapeutics-appoints-christine-silverstein-as-vice-president-investor-relations-nasdaq-abeo-2120697.htm

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId188.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId193.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 29/38


"I see tremendous potential for the company. I look forward to conveying the value
proposition of the company to a diverse network of institutional and retail investors
and further broadening its reach within the investment community."


In our view, there's no reason for unsophisticated retail investors to be investing/gambling
(like Blech)/speculating in small cap biotech stocks: it's a swamp, and more times than we
can count, at the end of the day, we see retail investors losing their shirts because they
lack the analytical skills to arrive at the right answers or they lack a strong grasp on the
fundamentals even when all of the due diligence is done for them. Just our $0.02 (or
approximately ABEO's fair value).


But what about Rouhandeh? Perhaps he's put the clouded days of SmallCapsOnline
behind him and avoided making bullish calls on Access (now known as ABEO)? A book
published in 2008 stated that Rouhandeh was, "betting big on Access because he
believes the stock could hit $30 in three years". Former ABEO Chief Executive Officer and
current Chief Operating Officer, Jeffrey Davis, chimed in touting that the company's drug
(Prolindac), "was markedly superior to Eloxatin [a competitive drug] in roughly half of all
tumor types".


Access even issued a press release alerting investors of this exciting development. At the
time, Access/ABEO was an OTC listed penny stock trading between a range of
$0.80­$3.50 per share, significantly above fair value by our estimates.


So how did Rouhandeh's $30 price target pan out? Using the issuance of the PR as the
start date, the stock had gotten nowhere near the delusional $30 per share price target
and instead ended up losing over 20% of its value by the 3 year anniversary date. To this
date, Rouhandeh's $30 price target has yet to be achieved, in fact, it never even got close.


ABEO's Obscure Tiny Texas Auditor Currently Entangled in UDF "Ponzi­Like
Scheme" Allegations; Expresses Substantial Doubt about ABEO as a Going
Concern:


In what has to be some sort of record, ABEO's auditor issued 8 "unqualified going
concern" opinions from 2006 to present, according to SEC filings. For those unfamiliar
with this language and its significance; it's basically a polite way for the auditor to "alert the
market that a company might fail." Given the huge cash shuffle out of ABEO and into the
pockets of insiders, combined with the shocking losses the company has generated over
time, we're not that surprised that ABEO is perpetually on the brink of insolvency.



https://books.google.com/books?id=cSXom-aFtUAC&pg=PA154&lpg=PA154&dq=Gene+Marcial

http://www.fiercehealthcare.com/healthcare/access-pharmaceuticals-highlighted-gene-marcial-s-new-book-7-commandments-stock

https://www.bamsec.com/filing/31830610000018/1?entity_id=318306&table=42

http://lexicon.ft.com/Term?term=going%20concern%20opinion
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 30/38


If you are an investor in ABEO, I encourage you to review the reports yourself and in the
future I would highly recommend you read what the auditors have to say before you
decide to day trade and lose all of your money on penny stocks: FY 2013, FY 2012, FY
2011, FY 2010, FY 2009, FY 2008, FY 2007, FY 2006.


There's no doubt that auditors are important and that's why it's worth reviewing the
potential qualifications of ABEO's auditor, Whitley Penn LLP. Right out of the gate we
found that the Public Company Accounting Oversight Board found an audit deficiency at
Whitney Penn in 2015 and several audit deficiencies in 2007.


Source: Public Company Accounting Oversight Board


We've highlighted the second failure because ABEO has an extensive history regarding
related party loans. To be clear, PCAOB does not disclose which company these audit
deficiencies came from in their inspection report but given that Whitley Penn LLP has
conducted more audits for ABEO than any other public client (according to Capital IQ),
there's a non­zero probability that this could be referring to ABEO.


In a Prospectus filing under a section titled "Transactions with Related Persons,
Promoters and Certain Control Persons" ABEO discloses that it had made substantial
loans to executive officers, according to ABEO's own SEC filings:


" As of December 31, 2008, principal and interest on the notes was: Mr. Gray ­
$908,000; Dr. Nowotnik ­ $454,000; and Mr. Thompson ­ $272,000. In accordance
with the Sarbanes­Oxley Act of 2002, we no longer make loans to our executive
officers. Interest on the notes is neither being collected nor accrued. "


Source: ABEO Prospectus


There's nothing really left to say here but being able to trust the auditors and their ability to
conduct the correct procedures is vital. Just ask the investors in United Development
Funding which were probably shocked to find out that Whitley Penn LLP was also their



https://www.bamsec.com/filing/31830614000006/1?entity_id=318306&hl=149754:149854&hl_id=41t4pwvgz

https://www.bamsec.com/filing/31830613000004/1?entity_id=318306&hl=157708:157808&hl_id=ek5r6wdff

https://www.bamsec.com/filing/31830612000020/1?entity_id=318306&hl=160035:160135&hl_id=nj68abpzf

https://www.bamsec.com/filing/31830611000002/1?entity_id=318306&hl=161423:161523&hl_id=v1fkabwmg

https://www.bamsec.com/filing/31830610000018/1?entity_id=318306&hl=200795:200895&hl_id=ejz5tbwzz

https://www.bamsec.com/filing/31830609000007/1?entity_id=318306&hl=250641:250741&hl_id=e1siazdzf

https://www.bamsec.com/filing/31830608000016/1?entity_id=318306&hl=238673:238773&hl_id=ey_0azdzg

https://www.bamsec.com/filing/31830607000012/1?entity_id=318306&hl=250510:250622&hl_id=4knxrzwzg

https://pcaobus.org/Inspections/Reports/Documents/2014-Whitley-Penn.pdf

https://pcaobus.org/Inspections/Reports/Documents/2007_Whitley_Penn.pdf

https://pcaobus.org/Inspections/Reports/Documents/2007_Whitley_Penn.pdf

https://www.bamsec.com/filing/114036108006400/1?entity_id=318306&hl=900631:900687&hl_id=4kyfhcazf

https://www.bamsec.com/filing/31830607000037/1?entity_id=318306&hl=1328014:1328056&hl_id=eyi5rc0fz

https://www.bamsec.com/filing/31830608000070/1?entity_id=318306&hl=1451521:1451553&hl_id=4j53r5azz

https://www.bamsec.com/filing/31830610000011/1?entity_id=318306&hl=383258:383562&hl_id=4yi2vbhmz

https://www.bamsec.com/filing/31830610000011/1?entity_id=318306&hl=383258:383562&hl_id=4yi2vbhmz

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId211.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 31/38


auditor after a hedge fund exposed the Ponzi­like scheme and even sent a letter to
Whitley Penn spoon feeding them the details of all the red flags that were found:


Source: UDF Exposed


The UDF entities specifically named here quickly lost substantial amounts of their value.
One of the entities even appears to have went through a 6+ month trading halt. For the
more visually inclined, here's what an investor in these entities would have had to live
with:


Source: Capital IQ


In my opinion, after reviewing materials published publicly, we believe there is very little
chance investors will recoup their losses and this will likely be a devastating but
permanent loss of capital for those that put too much trust in a small unknown auditor.



http://www.pionline.com/article/20160218/ONLINE/160219868/fbi-investigating-united-development-funding

https://udfexposed.com/facts

https://udfexposed.com/

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId219.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId221.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 32/38


Unfortunately, this is not where Whitley Penn's problems end. After reviewing the firm's top
audit clients provided by Capital IQ, we noticed that Whitley Penn frequently provided
audit services to penny stocks that have a history of destroying a significant amount of
shareholder value as shown by the inception to date estimated returns, also provided by
Capital IQ:


Source: Data Provided by Capital IQ


When you compare the market capitalizations in the table, you'll notice that ABEO is an
extreme outlier. The relatively high market capitalization should not be confused as a sign
of quality, ABEO had a market cap of less than $10 million at the end of 2014 and the
current market cap is a reflection of the ongoing stock promotion based on the faulty
science we debunked in the first half of this report, in my opinion.


Debunking the Retail Bull Case: Retail Shareholders Fooled by Soros Deal


Many retail investors appear to be confused about Soros' ABEO ownership and
improperly assign too much value to his name appearing as a shareholder. This is a
common rookie mistake.


First it's worth addressing that Soros has invested a miniscule amount into ABEO, it didn't
even account for more than 0.02% of his 13F holdings when the position initially appeared
in the SEC document. Secondly, ABEO was desperate for cash and had to sweeten the
deal with warrants which significantly diluted common shareholders. The table below
shows that even today Soros' ABEO position is less than 0.40% of his 13F holdings:


Source: Capital IQ


We can see that Soros participated in the December 2014 financing because his 13F
discloses that he held shares specifically issued during that deal, the tell being the PTBIW
representing the warrants. Warrants are a common sweetener in low quality equity deals.



https://www.bamsec.com/filing/114036115007300/2?entity_id=1029160&hl=8512:8659&hl_id=4kr6s8rzz

https://www.bamsec.com/filing/114420416091600/1?entity_id=318306&hl=51831:52796&hl_id=4joqhurzg

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId223.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId225.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 33/38


Note that until recently, Abeona went by the name PlasmaTech Biophamaceuticals (PTBI).


Source: 13F Holdings


Note 9 in ABEO's annual report shows that the December 2014 financing allowed this
group of investors to acquire millions of shares at a discounted cost basis. Pricing a deal
with a high level of warrant coverage typically means the deal was difficult to place with
institutional investors, and that the investors that did agree to the deal required a "can't
lose" type of discount in order to take the risk.


In my opinion, based off these disclosures it's pretty clear that this is absolutely not a
conviction bet for Soros and he essentially was handed discounted "can't lose" shares at
the expense of ordinary shareholders who got diluted. In fact, these types of "investor of
last resort" deals are not uncommon in unsavory microcap stocks. It's entirely possible
that Soros has little or no view on the actual company, and that one of his employees
simply participated in the deal because it came at such a big discount. In my view, the
Soros bull case is actually just another example of how ABEO retail investors got the short
end of the stick.


Further, we think investors would be wise to recognize that someone with a cost basis
below current trading prices and likely a fraction of what retail investors paid for their
shares, might be inclined and/or motivated to aggressively sell their shares at any price
above the cost basis. This is the "can't lose" situation we described earlier, if Soros
decided to sell his shares he would still make a substantial profit. Those that bought the
recent hype surrounding ABEO shares would be operating from an extremely
disadvantaged position compared to Soros due to their high cost basis and therefore
would be selling to limit the losses and inevitable pain associated with such severe
drawdowns.


ABEO Valuation


Below we will look at a scenario analysis of valuation methods to reach a price target on
ABEO.


Upside Case: Valuation Based on Historical Market Cap



http://www.marketwired.com/press-release/plasmatech-biopharmaceuticals-announces-name-change-abeona-therapeutics-reflect-broader-nasdaq-ptbi-2031347.htm

https://www.bamsec.com/filing/114036115007300/2?entity_id=1029160&hl=8512:8659&hl_id=4kr6s8rzz

https://www.bamsec.com/filing/114420416091600/1?entity_id=318306&hl=213855:214655&hl_id=v1zuldrgm

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId228.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 34/38


ABEO is currently trading near the highest market capitalization in its history. Below you
can see that ABEO has rarely traded higher than its current market capitalization and that
the stock typically collapses after reaching such extreme and unsustainable valuations:


Source: Capital IQ


Many investors mistakenly believe the shares are "cheap" because of the low dollar figure
­ this is not true. Abeona shares remain incredibly expensive at ~$200 million of market
cap for, as far as we can tell, essentially nothing of value. The share price is "low"
because of the unrelenting dilution shareholders have been subjected to. The following
dilution and long­term price charts make this clear:


Source: Capital IQ



https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId233.png

https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId234.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 35/38


Source: Capital IQ


The historical average market cap is about $30 million. Abeona's share count is
approximately 40 million. With this method we derive a $0.75 ($30m / 40m) upside
scenario price target based on the assumption that ABEO stock should mean revert to its
historical market cap over time.


We admit this is likely far too optimistic of a valuation level for ABEO but that's what
makes markets and the bulls need something to play for.


Base Case: The Fundamentals


We actually don't think ABEO has any fundamentals based on our view that the
company's science will be an abject failure. We therefore value ABEO based on its
balance sheet. Our method involves projecting the forward cash balance ABEO may have
12 months from now based on the trailing cash burn rate and the current amount of net
cash on the balance sheet:



https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId235.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 36/38


Source: Public Available Filings & Mako Estimates


Using this method, we reach a fair value estimate of $0.40 per share, representing
downside of ~92%.


Downside Case: Mako's Proprietary Charting Algorithm


Lastly, we have developed what we believe to be a highly sophisticated proprietary
process for predicting the future of ABEO's stock price. The logic is straightforward: by
assembling the returns of Rouhandeh's other high profile disasters including MacroChem
and Somanta, which are now both subsidiaries of ABEO, we can use the most
sophisticated machine learning algorithms available today to estimate what the future
returns of ABEO are likely to be:



https://www.bamsec.com/filing/31830609000007/2?cik=318306
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 37/38


Source: Capital IQ & Internal Proprietary Estimates


ABEO has experienced similar declines in its past so this projected estimated trading
pattern is credible in our view and we strongly believe that ABEO's shares are currently
moseying down this path. Under this scenario, we believe fair value approximates $0.00
per share.


Conclusion: Blended Valuation Average Implies 95% Downside


We take a blended, equally weighted average of these price targets: ($0.75 + $0.40 +
$0.00) / 3 = $0.38 estimated fair value per share, representing downside of 92% for ABEO
shares from the current level of $5.15.


Based on our price target, we rate ABEO a strong sell.


Management Response


We called the company's Dallas­based offices and were unable to reach management by
phone.


Disclosure: I am/we are short ABEO. I wrote this article myself, and it expresses my own opinions. I am not receiving
compensation for it. I have no business relationship with any company whose stock is mentioned in this article.



https://static.seekingalpha.com/uploads/2016/12/40228756_14814133869997_rId238.png
7/7/2019 Abeona: Stock Promotions, Fraud Convictions, And Demonstrably Unviable Science - A Sell With 92% Downside - Abeona Therapeutics Inc. (NASDA…


https://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-92-percent 38/38


JOIN THE CONVERSATION


Comments (77)


black_belt
Also mako ­I have a serious question for you. You state in your "research" that there are serious competitors with
superior technology and then you name them ­ lysogene, Shire and QURE. If they are superior, why have Shire and
QURE discontinued the development of their projects?


My research suggests that there are only three companies with late stage MPS3 drugs ­ Alexion, Biomarin and
Abeona. For some reason you failed to mention Alexion and Biomarin where there data does not look too bad. The
Alexion and Abeona data looks quite comparable but obviously your "research" omits any human clinical trial data
which will be used by the FDA to base an approval decision on.


12 Dec 2016, 11:52 PM



https://seekingalpha.com/user/47839712
